SEARCH

SEARCH BY CITATION

References

  • 1
    Drossman DA, Whitehead WE, Camilleri M for the American Gastroenterological Association Patient Care Committee. Irritable bowel syndrome: a technical review for practice guideline development. Gastroenterology 1997; 112: 212037.
  • 2
    Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Müller-Lissner SA. Functional bowel disorders and functional abdominal pain. Gut 1999; 45(Suppl. II): II437.
  • 3
    Agreus L, Svärdsudd K, Nyren O, Tibblin G. Irritable bowel syndrome and dyspepsia in the general population: overlap and lack of stability over time. Gastroenterology 1995; 109: 67180.
  • 4
    Drossman DA, Li Z, Andruzzi E, et al. U.S. householder survey on functional gastrointestinal disorders. Dig Dis Sci 1993; 38: 156980.
  • 5
    Heaton KW, O'Donnell LJD, Braddon FEM, Mountford RA, Hughes AO, Cripps PJ. Symptoms of irritable bowel syndrome in a British urban community. Consulters and non-consulters. Gastroenterology 1992; 102: 19627.
  • 6
    Jones R, Lydeard S. Irritable bowel syndrome in the general population. Br Med J 1992; 304: 8790.
  • 7
    Talley NJ, Zinsmeister AR, Van Dyke C, Melton LJ III. Epidemiology of colonic symptoms and the irritable bowel syndrome. Gastroenterology 1991; 101: 92734.
  • 8
    Camilleri M, Choi MG. Review article: irritable bowel syndrome. Aliment Pharmacol Ther 1997; 11: 315.
  • 9
    Patee PL, Thompson WG. Drug treatment of the irritable bowel syndrome. Drugs 1992; 44: 2006.
  • 10
    Pace F, Coremans G, Dapoigny M, et al. Therapy of irritable bowel syndrome — an overview. Digestion 1995; 56: 43342.
  • 11
    ICH Biostatistics. ICH Biostatistics Guideline. ICH Harmonized Tripartite Guideline. Note for Guidance on Statistical Principles for Clinical Trials. ICH Topic E9, Step 4, Consensus Guideline. Town: ICH Biostatistics, 1998.
  • 12
    Wei LJ, Lachin JM. Two-sample asymptotically distribution-free tests for incomplete multivariate observations. J Am Stat Assoc 1984; 79: 65361.
  • 13
    Gillings D, Koch G. The application of the principle of intention-to-treat to the analysis of clinical trials. Drug Inform J 1991; 25: 41124.
  • 14
    Colditz GA, Miller JN, Mosteller F. Measuring gain in the evaluation of medical technology: the probability of a better outcome. Int J Technol Assess Health Care 1988; 4: 63742.
  • 15
    Okpanyi SN, Mark M, Wahl MA. Gastrointestinal motility modulation with Iberogast®. Acta Horticult 1993; 3332: 22735.
  • 16
    Simmen U, Kelber O, Jäggi R, Büter B, Okpanyi SN, Weiser D. Relevance of the herbal combination of STW 5 for its binding affinity to the muscarinic M3 receptor. Naunyn-Schmiedeberg's Arch Pharmacol 2003; 367(Suppl. 1A): R22.
  • 17
    Talley NJ. Serotoninergic neuroenteric modulators. Lancet 2001; 358: 20618.
  • 18
    Lacy BE, Yu SJ. Tegaserod. A new 5-HT4 agonist. Clin Gastroenterol 2002; 1: 2733.
  • 19
    Akehurst R, Kaltenthaler E. Treatment of irritable bowel syndrome: a review of randomised controlled trials. Gut 2001; 48: 27282.
  • 20
    Klein KB. Controlled treatment trials in the irritable bowel syndrome: a critique. Gastroenterology 1988; 95: 23241.
  • 21
    Veldhuyzen van Zanten SJ, Talley NJ, Bytzer P, Klein KB, Whorwell PJ, Zinsmeister AR. Design of treatment trials for functional gastrointestinal disorders. Gut 1999; 45(Suppl. 2): 6977.
  • 22
    Bensoussan A, Talley NJ, Hing M, Menzies R, Guo A, Ngu M. Treatment of irritable bowel syndrome with Chinese herbal medicine: a randomized controlled trial. J Am Med Assoc 1998; 280: 15859.
  • 23
    Buchert D. Wirkung einer fixen Kombination bei gesicherter Non-Ulcus-Dyspepsie. Z Phytother 1994; 15(1): 245.
  • 24
    Holtmann G, Madisch A, Hotz J, et al. Treatment of functional dyspepsia with a herbal preparation — results of a double-blind, randomized, placebo-controlled, multicenter trial. Gastroenterology 1999; 116: AG0275.
  • 25
    Madisch A, Melderis H, Mayr K, Sassin I, Hotz J. Commercially available herbal preparation and its modified dispense in patients with functional dyspepsia. Results of a double-blind, placebo-controlled, randomized multicenter trial. Z Gastroenterol 2001; 39: 5117.
  • 26
    Holtmann G, Goebell H, Talley NJ. Functional dyspepsia and irritable bowel syndrome: is there a common pathophysiological basis? Am J Gastroenterol 1997; 92: 9549.
  • 27
    Khayyal MT, El-Ghazaly MA, Kenawy SA, et al. Antiulcerogenic effect of some gastrointestinally acting plant extracts and their combination. Arzneim-Forsch/Drug Res 2001; 15: 54553.
  • 28
    Poynard T, Naveau S, Mory B, Chaput JC. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 1994; 8: 49910.
  • 29
    Dew MJ, Evans BK, Rhodes J. Peppermint oil for the irritable bowel syndrome: a multicentre trial. Br J Clin Pract 1995; 38: 394.
  • 30
    Rees WD, Evans BK, Rhodes J. Treating irritable bowel syndrome with peppermint oil. Br Med J 1979; 2: 8356.
  • 31
    Duthie HL. The effect of peppermint oil on colonic motility in man. Br J Surg 1981; 68: 8204.
  • 32
    Liu JH, Chen GH, Yeh HZ, Huang CK, Poon SK. Enteric-coated peppermint-oil capsules in the treatment of irritable bowel syndrome: a prospective, randomised trial. J Gastroenterol 1997; 32: 7658.
  • 33
    Hills JM, Aaronson PI. The mechanism of action of peppermint oil on gastrointestinal smooth muscle. An analysis using patch clamp electrophysiology and isolated tissue pharmacology in rabbit and guinea pig. Gastroenterology 1991; 101: 5565.
  • 34
    Pittler MH, Ernst E. Peppermint oil for irritable bowel syndrome: a critical review and metaanalysis. Am J Gastroenterol 1998; 93: 11315.
    Direct Link:
  • 35
    Benninger J, Schneider HT, Schuppan D, Kirchner T, Hahn EG. Acute hepatitis induced by greater celandine (Chelidonium majus). Gastroenterology 1999; 117: 12347.
  • 36
    Kane JA, Kane SP, Jain S. Hepatitis induced by traditional Chinese herbs. Gut 1995; 36: 1467.
  • 37
    Delvaux M, Louvel D, Mamet JP, Campos-Oriola R, Frexinos J. Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome. Aliment Pharmacol Ther 1998; 12: 84955.
  • 38
    Jones RH, Holtmann G, Rodrigo L, et al. Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients. Aliment Pharmacol Ther 1999; 13: 141927.